Related Experiment Video
Updated: Mar 28, 2026
05:31
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
1.5K
Antiphospholipid syndrome and pregnancy-a hematologic perspective
Andrew J Doyle1, Catrin Cox1, Karen A Breen1
1Haemostasis and Thrombosis Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Research and Practice in Thrombosis and Haemostasis
|March 27, 2026
Summary
Antiphospholipid syndrome (APS) in pregnancy poses significant risks for thrombosis and adverse outcomes. This review focuses on hematologic management strategies to improve pregnancy outcomes for women with APS.
Area of Science:
- Hematology
- Autoimmune Disorders
- Reproductive Medicine
Background:
- Antiphospholipid syndrome (APS) is a multisystem autoimmune disorder linked to thrombosis and obstetric complications.
- Pregnancy in APS patients presents complex challenges, including high risks of thrombosis and adverse pregnancy outcomes.
- Despite advancements since 1983, diagnosing APS and managing its pregnancy complications require further improvement, particularly in risk stratification and treatment.
Purpose of the Study:
- To provide a hematologic perspective on managing Antiphospholipid Syndrome (APS) during pregnancy.
- To discuss pre-pregnancy counseling and focus on late adverse pregnancy outcomes and thrombosis management in APS.
- To summarize recent advancements and data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Main Methods:
- Review of current literature and recent data presented at the 2025 ISTH Congress.
- Focus on hematologic management strategies for Antiphospholipid Syndrome (APS) in pregnancy.
- Emphasis on late adverse pregnancy outcomes and thrombosis management, with discussion on pre-pregnancy counseling.
Main Results:
- Antiphospholipid syndrome (APS) management during pregnancy remains challenging, with ongoing needs in risk stratification and treatment optimization.
- Hematologic strategies are crucial for mitigating thrombosis and improving late adverse pregnancy outcomes in APS patients.
- Recent data highlights the complexities and potential advancements in managing APS during pregnancy.
Conclusions:
- Optimal hematologic management and pre-pregnancy counseling are essential for improving pregnancy outcomes in women with Antiphospholipid Syndrome (APS).
- Continued research is vital to address the challenges in risk stratification and develop novel treatments for APS during pregnancy.
- The 2025 ISTH Congress provided valuable insights into the latest developments in understanding and managing APS in the context of pregnancy.
Related Concept Videos
01:19Rh Blood Group
4.2K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
4.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:30Venous Thrombosis IV: Nursing Management
372
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
372
01:30Venous Thrombosis I: Introduction
677
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
677
01:07Teratogenicity
4.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K